Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid Sells 403 Shares

Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Johnson & Johnson Trading Up 1.9 %

JNJ opened at $157.93 on Thursday. The firm has a market cap of $380.23 billion, a P/E ratio of 23.75, a P/E/G ratio of 2.50 and a beta of 0.52. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $148.34 and a 200 day moving average of $155.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.14%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Institutional Trading of Johnson & Johnson

Institutional investors have recently added to or reduced their stakes in the company. AMF Tjanstepension AB raised its stake in shares of Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $209,000. Wealth Group Ltd. bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $213,000. Swedbank AB raised its stake in shares of Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after acquiring an additional 111,570 shares in the last quarter. Finally, Schaper Benz & Wise Investment Counsel Inc. WI raised its stake in shares of Johnson & Johnson by 1.8% during the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company’s stock valued at $15,798,000 after acquiring an additional 1,768 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Guggenheim upped their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Raymond James dropped their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Barclays increased their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.